中国癌症杂志 ›› 2019, Vol. 29 ›› Issue (7): 481-485.doi: 10.19401/j.cnki.1007-3639.2019.07.001

• 专家述评与论著 • 上一篇    下一篇

嵌合抗原受体T细胞治疗胰腺癌的现状及未来策略

潘泽雁  综述 ,湛先保  审校   

  1. 海军军医大学附属长海医院肿瘤科,上海 200433
  • 出版日期:2019-07-30 发布日期:2019-07-12
  • 通信作者: 湛先保 E-mail: zhanxianbao@126.com

Current status and future strategies of chimeric antigen receptor T-cells in the treatment of pancreatic cancer

PAN Zeyan, ZHAN Xianbao   

  1. Department of Oncology, Changhai Hospital Affiliated to the Naval Military Medical University, Shanghai 200433, China
  • Published:2019-07-30 Online:2019-07-12
  • Contact: ZHAN Xianbao E-mail: zhanxianbao@126.com

摘要: 嵌合抗原受体(chimeric antigen receptor,CAR)T细胞作为肿瘤免疫治疗领域的新兴疗法在B细胞系血液系统肿瘤中已经获得了较为满意的疗效,因此,CAR-T细胞疗法也被列为包括胰腺癌在内的实体肿瘤治疗的新探索方向。尽管实体瘤本身的异质性、微环境的复杂性导致单纯的CAR-T细胞治疗效果不尽如人意,但随着新技术的开发,CAR结构的优化,各种免疫佐剂的联合应用使CAR-T细胞疗法值得进一步研究。该文就CAR-T细胞疗法的特点、治疗胰腺癌的现状及未来方向进行概述。

关键词: 嵌合抗原受体T细胞, 胰腺癌, 免疫治疗

Abstract:  Chimeric antigen receptor (CAR) T-cells have recently provided promising advances as a novel immunotherapeutic approach for cancer treatment especially in B-cell malignancies. CAR T-cell therapy represents an emerging therapeutic option for pancreatic cancer as well. It has shown less success against solid tumors due to heterogeneity of the solid tumor and the specific characteristics of the tumor microenvironment. With development of the new technologies, optimization of CAR structure combined with other therapeutic immunologic adjuvants shows promising results in some clinical trials. This review summarized characteristics of CAR T-cell therapy, its current status in the treatment of pancreatic cancer and the strategies for future treatment.

Key words: Chimeric antigen receptor T-cells, Pancreatic cancer, Immunotherapy